ClinicalTrials.gg
CompletedNCT03460405Updated Feb 20, 2020

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants

A Phase 2 interventional study of Vi-DT Vaccine and Vi Polysaccharide Vaccine in Safety Issues and Immunogenicity, sponsored by PT Bio Farma. Completed at 2 sites in Indonesia. Open to participants aged 6 Months to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-20.

Sponsored by PT Bio Farma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
6 Months to 40 Years
Sex
All
01

Study summary

This study is to assess the safety and immunogenicity of Vi-DT vaccine in adults, adolescent, children and infants.

Read the detailed description

To describe the safety of this vaccine following one dose immunization in adults, adolescent, children and infants.

To assess immunogenicity following one dose of Vi-DT vaccine immunization. To compare the safety and immunogenicity of Vi-DT to Vi polysaccharide vaccine in adults, adolescents, and children groups.

To compare the safety and immunogenicity of Vi-DT to IPV vaccine in infants groups.

Kinetics of Vi-specific IgG antibodies up to 6 months and 1 year after administration of 1 dose of vaccine.

To evaluate the safety and immunogenicity of Vi-DT co-administered with MR vaccine in infants (≥ 9months -23 months old).

To evaluate the safety and immunogenicity of MR vaccine co-administered with Vi-DT vaccine in infants (≥ 9months -23 months old).

02

Conditions studied

  • Safety Issues
  • Immunogenicity
03

In context

Lead sponsor

PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. Healthy
  2. Subjects/Parents have been informed properly regarding the study and signed the form
  3. Subject/parents/legal guardians will commit themselves to comply with the instructions of the investigator and the schedule of the trial.

Exclusion Criteria For adults-adolescent-children:

  1. Subject concomitantly enrolled or scheduled to be enrolled in another trial
  2. Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C)
  3. Known history of allergy to any component of the vaccines
  4. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection
  5. Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, therapy and other immunosuppresant).
  6. Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives
  7. Pregnancy \& lactation (Adults)
  8. Individuals who have previously received any vaccines against typhoid fever.
  9. Subjects already immunized with any vaccine within 1 month prior and expect to receive other vaccines within 1 month following immunization.
  10. Individuals who have a previously ascertained typhoid fever within 3 months prior to immunization.
  11. History of substance abuse (Adults).
  12. Subject planning to move from the study area before the end of study period.

Exclusion Criteria for infants:

  1. Subject concomitantly enrolled or scheduled to be enrolled in another trial
  2. Mother less than 18 years of age at the age of enrollment of the infant
  3. Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C)
  4. Known history of allergy to any component of the vaccines
  5. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection
  6. Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, corticosteroid therapy and other immunosuppresant).
  7. Any abnormality or chronic disease which according to the investigator might be compromised by the vaccination and/or interfere with the assessment of the trial objectives.
  8. Individuals who have previously received any vaccines against typhoid fever.
  9. Subjects already immunized with any vaccine within 1 month prior and expect to receive other vaccines within 1 month following immunization, except MR vaccine.
  10. Individuals who have a previously ascertained typhoid fever within 3 months prior to immunization.
  11. Subject planning to move from the study area before the end of study period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    VI-DT vaccine (adults,adolescent)

    1 dose of 0.5 ml Vi-DT vaccine

    Biological: Vi-DT Vaccine

  • Active comparator
    Vi polysaccharide (adults,adolescent)

    1 dose of 0.5 ml Vi polysaccharide vaccine

    Biological: Vi Polysaccharide Vaccine

  • Experimental
    VI-DT vaccine (children)

    1 dose of 0.5 ml Vi-DT vaccine

    Biological: Vi-DT Vaccine

  • Active comparator
    Vi polysaccharide vaccine (children)

    1 dose of 0.5 ml Vi polysaccharide vaccine

    Biological: Vi Polysaccharide Vaccine

  • Experimental
    VI-DT vaccine (infants)

    1 dose of 0.5 ml Vi-DT vaccine

    Biological: Vi-DT Vaccine

  • Active comparator
    IPV Vaccine (infants)

    1 dose of 0.5 ml IPV vaccine

    Biological: IPV Vaccine

Interventions

  • BiologicalVi-DT Vaccine

    1 dose of Vi-DT Vaccine

    Also known as: Typhoid Conjugate Vaccine

  • BiologicalVi Polysaccharide Vaccine

    1 dose of Vi Polysaccharide Vaccine

  • BiologicalIPV Vaccine

    1 dose of IPV Vaccine

06

What researchers measure

Primary outcomes

  1. Local reaction and systemic event after vaccination

    Percentage of subjects with at least one immediate reaction (local reaction or systemic event) after vaccination.

    Time frame: 28 days

Secondary outcomes

  1. Adverse events after vaccination

    Percentage of subjects with at least one of these adverse events, solicited or not, within 24 h, 48h, 72h and 28 days after 1 dose vaccination.

    Time frame: up to 28 days

  2. Serious adverse events after vaccination

    Number and percentage of subjects with serious adverse event from inclusion until 28 day after vaccination

    Time frame: 28 days

  3. Geometric Mean Titers (GMT)

    Geometric Mean Titers (GMT) 28 days following immunization

    Time frame: 28 days

  4. Percentage of subjects with increasing antibody titer >= 4 times

    Percentage of subjects with increasing antibody titer \>= 4 times in all subjects

    Time frame: 28 days

07

Study locations

2 sites
  • Puskesmas Jatinegara
    Jakarta, Indonesia
  • Puskesmas Senen
    Jakarta, Indonesia
08

References and documents

Publications

  • Medise BE, Soedjatmiko S, Gunardi H, Sekartini R, Satari HI, Hadinegoro SR, Wirahmadi A, Puspita M, Sari RM, Yang JS, Sil A, Sahastrabuddhe S, Bachtiar NS. A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report. BMC Pediatr. 2020 Oct 15;20(1):480. doi: 10.1186/s12887-020-02375-4. PubMed 33059607 ↗
  • Medise BE, Soedjatmiko S, Gunardi H, Sekartini R, Satari HI, Hadinegoro SR, Wirahmadi A, Puspita M, Sari RM, Yang JS, Sil A, Sahastrabuddhe S, Bachtiar NS. One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine. Int J Infect Dis. 2020 Apr;93:102-107. doi: 10.1016/j.ijid.2020.01.045. Epub 2020 Jan 28. PubMed 32004693 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Dec 2019, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2018
First posted
Mar 9, 2018
StartActual
Jul 16, 2018
Primary completionActual
Dec 31, 2019
CompletionActual
Jan 30, 2020
Last update
Feb 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03460405
Lead sponsor
PT Bio Farma
Responsible party
Sponsor
First posted
Mar 9, 2018
Start date
Jul 16, 2018
Primary completion
Dec 31, 2019
Completion
Jan 30, 2020
Last update
Feb 20, 2020

Study contacts

Bernie Endyarni, MD
principal investigator · Faculty of Medicine, University of Indonesia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion